[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pharmacogenetics\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pharmacogenetics":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,55,92,120],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":43,"lastUpdatePostDateStruct":44,"startDateStruct":47,"completionDateStruct":49,"leadSponsor":51,"locationsCount":54},"100621657","an-evaluation-of-the-impact-of-pharmacist-comprehensive-medication-management-with-pharmacogenomic-results-to-improve-depression-outcomes-in-community-pharmacies-100621657",false,"NCT07373470","An Evaluation of the Impact of Pharmacist Comprehensive Medication Management With Pharmacogenomic Results to Improve Depression Outcomes in Community Pharmacies.","Genotype-guided Comprehensive Medication Management to Improve Depression Outcomes in Pennsylvania","COMPASS-PGx","INCLUSION CRITERIA:\n\n* At targeted community pharmacy for:\n\n  * New prescription or change in dose\u002Fschedule of SSRI (citalopram, escitalopram, sertraline, paroxetine), OR\n  * Concurrent SSRI (citalopram, escitalopram, sertraline, paroxetine) and new prescription\u002Fchange in SNRI (desvenlafaxine, duloxetine, and venlafaxine) \u002F bupropion.\n* Depressive symptoms confirmed by PHQ8 assessment (\\>5 indicating at least mild depressive symptoms)\n* UPMC patient (or able\u002Fwilling to become one) and has UPMC provider (or able\u002Fwilling to obtain one)\n* Signed consent to join Pitt+Me Discovery biobanking research study.\n* English-speaking\n\nEXCLUSION CRITERIA:\n\n* Inability to receive CMM at specific pharmacy\u002Fpharmacist\n* Comorbid diagnosis of schizophrenia (patient-reported)\n* Untreated sleep disorder (patient-reported)\n* Pitt+Me Discovery participant who has elected to not receive return of results, or who has already received results previously","ALL","18 Years",{"count":20,"type":21},220,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this prospective, randomized clinical trial is to learn whether pharmacogenomic (PGx)-guided comprehensive medication management delivered by pharmacists in community pharmacies will improve antidepressant treatment outcomes.\n\nThe primary aim is to determine whether comprehensive medication management with review of PGx testing results improves depression symptoms, compared with usual care.\n\nParticipants 18 years of age or older who have undergone PGx testing (e.g. through an independent biobanking study (Pitt+Me Discovery) who require initiation or adjustment of antidepressant therapy will be randomly assigned to receive either PGx-guided comprehensive medication management or usual care. Those who receive usual care will receive their PGx results at the end of the study. Researchers will compare the groups to assess whether PGx-guided care provided in partnership with community pharmacists and prescribers results in better depression and medication outcomes.",[27,28,29,30],"Pharmacogenetics","Depression - Major Depressive Disorder","Pharmacogenomic Drug Interaction","Community Pharmacy Services",[32,33,34,35,36,37,38,39,40,41],"precision medicine","pharmacogenomics","PGx","Comprehensive medication management","pharmacist","community pharmacy","medication review","antidepressants","pharmacogenomic testing","management of depression","NOT_YET_RECRUITING","2026-04-06",{"date":45,"type":46},"2026-04-08","ACTUAL",{"date":48,"type":21},"2026-04",{"date":50,"type":21},"2026-12-31",{"name":52,"class":53},"University of Pittsburgh","OTHER",1,{"id":56,"slug":57,"hasResults":11,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":61,"eligibilityCriteria":62,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":63,"targetDuration":4,"studyType":22,"phases":65,"briefSummary":66,"conditions":67,"keywords":71,"overallStatus":81,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":91},"100587526","pharmacogenomics-supported-psychotropic-prescribing-trial-100587526","NCT06929533","Pharmacogenomics-Supported Psychotropic Prescribing Trial","Pharmacogenomics-Supported Psychotropic Prescribing Trial (PGx-SUPPORT): A Pilot Implementation Study in Manitoba","PGx-SUPPORT","Inclusion Criteria:\n\n* Aged 18 years or older\n* The initiation, change, dose adjustment, or augmentation of psychotropic medication(s) is indicated\n* The treating clinician thinks PGx testing can benefit and refers the patient to the study\n\nExclusion Criteria:\n\n* Unwillingness to donate saliva samples for genetic analysis\n* History of liver or bone marrow (hematopoietic cell) transplantation\n* PGx testing results are already available\n* No personal health identification number (PHIN) is available",{"count":64,"type":21},200,[24],"Investigate the feasibility and utility of implementing pharmacogenetic testing for adults (aged 18 and older) seeking care for mental illness in Manitoba.",[68,27,69,70],"Mental Disorder","Adverse Drug Reaction (ADR)","Effectiveness",[72,73,74,27,75,76,77,78,79,80],"Adult","Mental Health","Psychiatry","Depression","Anxiety","OCD","Psychosis","Bipolar Disorder","mental illness","RECRUITING","2025-09-01",{"date":84,"type":46},"2025-09-08",{"date":86,"type":46},"2025-07-01",{"date":88,"type":21},"2030-12-31",{"name":90,"class":53},"University of Manitoba",2,{"id":93,"slug":94,"hasResults":11,"nctId":95,"briefTitle":96,"officialTitle":97,"acronym":98,"eligibilityCriteria":99,"healthyVolunteers":11,"sex":17,"minAge":100,"maxAge":4,"enrollmentInfo":101,"targetDuration":4,"studyType":103,"phases":4,"briefSummary":104,"conditions":105,"keywords":109,"overallStatus":81,"whyStopped":4,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":118,"locationsCount":54},"100436519","screening-of-susceptibility-genes-for-apap-induced-drug-induced-liver-injury-in-chinese-population-a-case-control-study-100436519","NCT04964310","Screening of Susceptibility Genes for APAP Induced Drug Induced LIver Injury in ChiNese Population: a Case-control Study","Pharmacogenomics of APAP Induced DILI in Chinese Population.","PAIN","Inclusion criteria：\n\n* A clear history of acetaminophen (or acetaminophen-containing drugs) ingestion.\n* Plasma and\u002For urine testing for acetaminophen components if history of ingestion is unclear.\n* Monitoring of Alanine aminotransferase (ALT) or Aspartate Aminotransferase (AST) ≥ 1000 IU\u002FL at any time after APAP administration and Roussel Uclaf Causality Assessment Method(RUCAM) score \\> 6\n* Age ≥ 14 years old\n* The subject or guardian agrees to participate in this project and signs an informed consent form.\n\nExclusion criteria：\n\n* The use of drugs for which frequency of adverse reactions to liver damage is defined as \"common or very common\" (≥1%) in the instructions.\n* Concurrent use of herbs that are clearly susceptible to liver damage (see list of definitions in the Annex).\n* Have a known definite cause of liver damage: active viral hepatitis; alcoholic liver disease; autoimmune liver disease; primary or secondary liver tumors; and other underlying liver disease that has affected liver function.\n* Those who fail to provide complete general information and clinical information.\n* Subjects or guardians who do not agree to see this project do not sign the informed consent form.","14 Years",{"count":102,"type":21},339,"OBSERVATIONAL","Acetaminophen (APAP) is the most commonly used NSAIDS in clinic, and it is also a common cause of drug-induced liver injury (DILI). In 2012, the proportion of DILI caused by APAP in the United States was 51%, while in Asia, it was only 7.10%. Previously, a small cohort study in the United States screened for some of the susceptibility genes for DILI due to APAP by the Genome wide association study (GWAS) method. However, the genetic susceptibility loci based on the US cohort were not applicable to the Chinese population. Therefore, we make a study design include Chinese population who ingested APAP and divided them into case group and control group according to the occurrence of DILI. We hope to be able to find the root of differences at the genetic level and explore new pathogenic mechanisms.",[106,107,27,108],"Acetaminophen","Drug-Induced Liver Injury","China",[106,107,27,108,110,111],"Case-Control Studies","candidate gene","2025-02-24",{"date":114,"type":46},"2025-02-26",{"date":116,"type":46},"2020-08-31",{"date":50,"type":21},{"name":119,"class":53},"The First Affiliated Hospital with Nanjing Medical University",{"id":121,"slug":122,"hasResults":11,"nctId":123,"briefTitle":124,"officialTitle":125,"acronym":4,"eligibilityCriteria":126,"healthyVolunteers":11,"sex":17,"minAge":127,"maxAge":4,"enrollmentInfo":128,"targetDuration":130,"studyType":103,"phases":4,"briefSummary":131,"conditions":132,"keywords":136,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":149,"lastUpdatePostDateStruct":150,"startDateStruct":152,"completionDateStruct":154,"leadSponsor":156,"locationsCount":4},"100458299","individual-risk-profiles-for-adverse-drug-reactions-in-geriatric-patients-100458299","NCT05247814","Individual Risk Profiles for Adverse Drug Reactions in Geriatric Patients","Individual Patient Risk Profiles for Adverse Drug Reactions: Establishing a Consecutive Research Cohort in an Interdisciplinary Polypharmacy Consultation Service of a Geriatric University Outpatient Department","Inclusion Criteria:\n\n* 70 years or older\n* Current drug therapy with three or more drugs\n* Being a patient in the interdisciplinary polypharmacy consultation service of the geriatric university outpatient clinic\n* Sufficient mobility (minimum: Wheelchair mobility)\n* Written informed consent of the patient or the legal representative\n\nExclusion Criteria:\n\n* No sufficient communication possible\n* Patients classified as terminally ill by the medical staff\n* Patients, that are incapable to give their informed consent and who do not have a legal representative","70 Years",{"count":129,"type":21},2000,"6 Months","This project will generate a prospective cohort of geriatric patients with polypharmacy which will be characterized for vulnerability profiles of adverse drug reactions.",[133,27,134,135],"Polypharmacy","Pharmacogenomic Testing","Drug-Related Side Effects and Adverse Reactions",[137,138,139,140,141,142,143,144,145,146,147,148],"Geriatric Assessment","Medication Adherence","Aged","Aged, 80 and over","Medication therapy management","Pharmacists","Geriatricians","Clinical Pharmacology","Medication reconciliation","Hospital pharmacy services","Hospital outpatient clinics","nterdisciplinary Health Team","2022-06-17",{"date":151,"type":46},"2022-06-23",{"date":153,"type":21},"2022-07",{"date":155,"type":21},"2032-02",{"name":157,"class":53},"RWTH Aachen University"]